| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Simon Cervenka, Sven E Pålhagen, Robert A Comley, Georgios Panagiotidis, Zsolt Cselényi, Julian C Matthews, Robert Y Lai, Christer Halldin, Lars Fard. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain : a journal of neurology. vol 129. issue Pt 8. 2006-09-29. PMID:16816393. |
support for dopaminergic hypoactivity in restless legs syndrome: a pet study on d2-receptor binding. |
2006-09-29 |
2023-08-12 |
human |
| Roberto Vetrugno, Manuela Contin, Agostino Baruzzi, Federica Provini, Giuseppe Plazzi, Pasquale Montagn. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society. vol 21. issue 2. 2006-09-25. PMID:16200540. |
augmentation, defined as a loss of circadian recurrence with progressively earlier daily onset and increase in the duration, intensity, and anatomy of symptoms, not compatible with the half-life of the drug, is associated with dopaminergic treatment in restless legs syndrome (rls) patients. |
2006-09-25 |
2023-08-12 |
Not clear |
| C Trenkwalde. The weight of evidence for ropinirole in restless legs syndrome. European journal of neurology. vol 13 Suppl 3. 2006-09-21. PMID:16930379. |
evidence-based guidelines consider dopaminergic therapy to be the mainstay of treatment for restless legs syndrome (rls). |
2006-09-21 |
2023-08-12 |
Not clear |
| Stephany Fulda, Thomas C Wette. Dopamine agonists for the treatment of restless legs syndrome. Expert opinion on pharmacotherapy. vol 6. issue 15. 2006-06-12. PMID:16316304. |
the aetiology of restless legs syndrome is unknown, but, beside genetic factors, the dopaminergic system may play a crucial role. |
2006-06-12 |
2023-08-12 |
Not clear |
| Chuan-Chia Chang, I-Shin Shiah, Hsin-An Chang, Wei-Chung Ma. Does domperidone potentiate mirtazapine-associated restless legs syndrome? Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 2. 2006-06-08. PMID:16309808. |
there is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome (rls). |
2006-06-08 |
2023-08-12 |
Not clear |
| Rajdeep S Kakar, Clete A Kushid. Ropinirole in the treatment of restless legs syndrome. Expert review of neurotherapeutics. vol 5. issue 1. 2006-04-18. PMID:15853472. |
the symptoms of restless legs syndrome are responsive to dopaminergic agents such as ropinirole. |
2006-04-18 |
2023-08-12 |
Not clear |
| S Qu, W G Ondo, X Zhang, W J Xie, T H Pan, W D L. Projections of diencephalic dopamine neurons into the spinal cord in mice. Experimental brain research. vol 168. issue 1-2. 2006-03-30. PMID:16044299. |
the aim of this study is to investigate the pathway of diencephalic dopaminergic (da) neuronal innervating into the spinal cord in mice, the pathway is postulated relevant to clinical restless legs syndrome (rls). |
2006-03-30 |
2023-08-12 |
mouse |
| Johannes Mathi. Update on restless legs. Swiss medical weekly. vol 135. issue 47-48. 2006-03-24. PMID:16511704. |
restless legs syndrome (rls) has become a well known disorder in the medical community in switzerland within the last ten years, particularly since the official introduction of dopaminergic drugs as first line treatment. |
2006-03-24 |
2023-08-12 |
Not clear |
| Sung-Wan Kim, Il-Seon Shin, Jae-Min Kim, Su-Jin Yang, Hee-Young Shin, Jin-Sang Yoo. Bupropion may improve restless legs syndrome: a report of three cases. Clinical neuropharmacology. vol 28. issue 6. 2006-03-02. PMID:16340389. |
restless legs syndrome (rls) is a common disorder for which agents that enhance dopaminergic activity, including dopamine agonists and levodopa, are the treatment of choice. |
2006-03-02 |
2023-08-12 |
Not clear |
| M Mrowka, M Jöbges, G Berding, N Schimke, M Shing, P Odi. Computerized movement analysis and beta-CIT-SPECT in patients with restless legs syndrome. Journal of neural transmission (Vienna, Austria : 1996). vol 112. issue 5. 2006-02-16. PMID:15517434. |
considering the positive effect of dopaminergic treatment on restless legs syndrome (rls), it has been suggested that the cause of rls may be linked to central dopaminergic dysfunction. |
2006-02-16 |
2023-08-12 |
Not clear |
| William G Ond. Restless legs syndrome. Current neurology and neuroscience reports. vol 5. issue 4. 2005-10-28. PMID:15987610. |
treatment of restless legs syndrome with dopaminergic medications is highly effective, although augmentation may occur eventually and require dosing flexibility. |
2005-10-28 |
2023-08-12 |
Not clear |
| Claudia Trenkwalder, Walter Paulus, Arthur S Walter. The restless legs syndrome. The Lancet. Neurology. vol 4. issue 8. 2005-08-25. PMID:16033689. |
dopaminergic treatment with levodopa and dopamine agonists is the first choice in idiopathic restless legs syndrome, but augmentation and rebound should be monitored in long-term treatment. |
2005-08-25 |
2023-08-12 |
Not clear |
| William G Ond. Methadone for refractory restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society. vol 20. issue 3. 2005-06-30. PMID:15580610. |
most cases of restless legs syndrome (rls) initially respond well to dopaminergic agonists. |
2005-06-30 |
2023-08-12 |
Not clear |
| Soichi Mizuno, Takumi Mihara, Tsuyoshi Miyaoka, Takuzi Inagaki, Jun Horiguch. CSF iron, ferritin and transferrin levels in restless legs syndrome. Journal of sleep research. vol 14. issue 1. 2005-06-30. PMID:15743333. |
the aim of this study is evaluating iron, ferritin, and transferrin in both serum and csf in patients of restless legs syndrome (rls), based on the hypothesis that iron deficiency in the central nervous system (cns) causes the symptoms as a result of the dysfunction of dopaminergic systems. |
2005-06-30 |
2023-08-12 |
Not clear |
| Diego Garcia-Borreguero, Carolina Serrano, Oscar Larrosa, Juan José Graniz. Circadian effects of dopaminergic treatment in restless legs syndrome. Sleep medicine. vol 5. issue 4. 2005-06-21. PMID:15223002. |
circadian effects of dopaminergic treatment in restless legs syndrome. |
2005-06-21 |
2023-08-12 |
Not clear |
| G G Tribl, T Sycha, N Kotzailias, J Zeitlhofer, E Auf. Apomorphine in idiopathic restless legs syndrome: an exploratory study. Journal of neurology, neurosurgery, and psychiatry. vol 76. issue 2. 2005-02-15. PMID:15654028. |
dopaminergic and opioidergic drugs have been found to be effective in patients with restless legs syndrome (rls). |
2005-02-15 |
2023-08-12 |
Not clear |
| Rainer Linke, Ilonka Eisensehr, Thomas-Christian Wetter, Franz-Josef Gildehaus, Gabriele Pöpperl, Claudia Trenkwalder, Soheyl Noachtar, Klaus Tatsc. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease? Movement disorders : official journal of the Movement Disorder Society. vol 19. issue 10. 2005-02-14. PMID:15390076. |
presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early parkinson's disease? |
2005-02-14 |
2023-08-12 |
Not clear |
| Rainer Linke, Ilonka Eisensehr, Thomas-Christian Wetter, Franz-Josef Gildehaus, Gabriele Pöpperl, Claudia Trenkwalder, Soheyl Noachtar, Klaus Tatsc. Presynaptic dopaminergic function in patients with restless legs syndrome: are there common features with early Parkinson's disease? Movement disorders : official journal of the Movement Disorder Society. vol 19. issue 10. 2005-02-14. PMID:15390076. |
the cause of restless legs syndrome (rls) is unknown, but an involvement of the dopaminergic system and a possible relation to parkinson's disease (pd) is suggested by the positive response to dopaminergic treatment. |
2005-02-14 |
2023-08-12 |
Not clear |
| Diego Garcia-Borreguero, Oscar Larrosa, Juan José Granizo, Yolanda de la Llave, Wayne A Henin. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. Sleep. vol 27. issue 4. 2004-10-21. PMID:15283001. |
to investigate circadian changes in dopaminergic function by means of a neuroendocrine challenge (growth hormone and prolactin responses to an acute oral administration of l-dopa) in patients with idiopathic restless legs syndrome (rls) and controls. |
2004-10-21 |
2023-08-12 |
Not clear |
| G G Tribl, S Asenbaum, S Happe, R M Bonelli, J Zeitlhofer, E Auf. Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep. Nuclear medicine communications. vol 25. issue 1. 2004-09-14. PMID:15061265. |
dopaminergic treatment is very effective in restless legs syndrome (rls) and periodic leg movements in sleep (plms). |
2004-09-14 |
2023-08-12 |
Not clear |